Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker struggles to find new areas of growth beyond its core portfolio of HIV medicines. Merdad Parsey, who ...

Gilead is hoping to break ground early next year on its Chess Hatch campus as part of its plans to expand its presence in ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google.

Hulu has unveiled a first look at “The Testaments,” the upcoming sequel series to “The Handmaid’s Tale.” The series, which is ...